MinervaX announces funding for Group B Streptococcus vaccine
December 15, 2022 -- Danish biotechnology company MinervaX ApS announced the completion of a 72-million-euro ($76.3 million) financing round to advance development of a novel vaccine against Group B Streptococcus (GBS). An equity financing of 22 million euros was co-led by new investors Trill Impact Ventures and Pureos Bioventures and existing investors. The European Investment Bank provided additional funding in a form of a 50-million-euro loan. Read More
Critical inhibitory site in enzyme leads to new antibiotic
December 12, 2022 -- Japanese researchers have discovered a new mechanism to allosterically inhibit a respiratory chain enzyme widely conserved across species. The research, published December 8 in the journal Nature Communications, identified an antibiotic effective against a drug-resistant strain of Neisseria gonorrhoeae based on their findings. Read More
B cells hinder intestinal healing, offer potential IBD drug target
December 5, 2022 -- New research reveals that B cells, white blood cells that are critical to the proper functioning of the immune system, greatly increase after bowel damage and prevent the tissue from healing. The findings have implications for the treatment of inflammatory bowel disease (IBD). Read More
Conferences
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
